Symbiotic relationship of pharmacogenetics and drugs of abuse.
- Authors
- Rutter, Joni L
- Year
- 2006
- Journal
- The AAPS journal
- PMID
- 16584126
- DOI
- 10.1208/aapsj080121
- PMCID
- PMC2751437
Pharmacogenetics/pharmacogenomics is the study of how genetic variation affects pharmacology, the use of drugs to treat disease. When drug responses are predicted in advance, it is easier to tailor medications to different diseases and individuals. Pharmacogenetics provides the tools required to identify genetic predictors of probable drug response, drug efficacy, and drug-induced adverse events-identifications that would ideally precede treatment decisions. Drug abuse and addiction genetic data have advanced the field of pharmacogenetics in general. Although major findings have emerged, pharmacotherapy remains hindered by issues such as adverse events, time lag to drug efficacy, and heterogeneity of the disorders being treated. The sequencing of the human genome and high-throughput technologies are enabling pharmacogenetics to have greater influence on treatment approaches. This review highlights key studies and identifies important genes in drug abuse pharmacogenetics that provide a basis for better diagnosis and treatment of drug abuse disorders.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders. | Burns JA et al. | — | 2019 | → |
| The Neuroscience of Drug Reward and Addiction. | Volkow ND et al. | — | 2019 | → |
| Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How. | Chen LS et al. | — | 2018 | → |
| Pathways to precision medicine in smoking cessation treatments. | Chen LS et al. | — | 2018 | → |
| Association between genetic variations of NMDA receptor NR3 subfamily genes and heroin addiction in male Han Chinese. | Xie X et al. | — | 2016 | → |
| Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. | Chen LS et al. | — | 2015 | → |
| Addiction science: Uncovering neurobiological complexity. | Volkow ND et al. | — | 2014 | → |
| Re-defininG AddiC(CH3)Tion: genomics and epigenomics on substance use disorders. | Rutter JL et al. | — | 2014 | → |
| Genomics and personalized medicine: <i>CHRNA5-CHRNA3-CHRNB4</i> and smoking cessation treatment. | Chen LS et al. | — | 2013 | → |
| Positive association between--1021TT genotype of dopamine beta hydroxylase gene and progressive behavior of injection heroin users. | Xie X et al. | — | 2013 | → |
| Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. | Chen LS et al. | — | 2012 | → |
| Addiction as a systems failure: focus on adolescence and smoking. | Baler RD et al. | — | 2011 | → |
| Ethical concerns related to developing pharmacogenomic treatment strategies for addiction. | Shields AE | — | 2011 | → |
| Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects. | Pilgrim JL et al. | — | 2011 | → |
| Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. | Mroziewicz M et al. | — | 2010 | → |
| Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment. | Khokhar JY et al. | — | 2010 | → |
| Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model. | Wu C et al. | — | 2009 | → |
| Frontiers in addiction research: celebrating the 35th anniversary of the National Institute on Drug Abuse. Sponsor's foreword. | Shurtleff D et al. | — | 2009 | → |
| Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready? | Shields AE et al. | — | 2008 | → |
| Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. | Heitjan DF et al. | — | 2008 | → |
| Indolealkylamines: biotransformations and potential drug-drug interactions. | Yu AM | — | 2008 | → |
| The effect of DHEA complementary treatment on heroin addicts participating in a rehabilitation program: a preliminary study. | Maayan R et al. | — | 2008 | → |
| Unintentional drug overdose death trends in New Mexico, USA, 1990-2005: combinations of heroin, cocaine, prescription opioids and alcohol. | Shah NG et al. | — | 2008 | → |
| Genetics and smoking cessation improving outcomes in smokers at risk. | Lerman CE et al. | — | 2007 | → |
| Translational research in medication development for nicotine dependence. | Lerman C et al. | — | 2007 | → |